VolitionRX VNRX 深 滬
等待開盤 09-08 09:30:00 美东时间
0.3496
0.000
-0.09%
華盛通- 最 高0.3496
- 今 開0.346
- 成交量 117.36万股
- 最 低 0.33
- 昨 收 0.3499
- 總市值 660.78万
- 52周最高 14.80
- 市盈率 靜 --
- 換手率 6.21%
- 52周最低 0.3269
- 委 比 0.00%
- 總股本 1890.11万
- 歷史最高 185.60
- 量 比 0.21
- 振 幅 5.60%
- 歷史最低 0.33
- 每 手 1
- 風險率 3.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations. The multi-national epigenetics firm demonstrated strong momen...
08-27 19:35
Pre-Bell Movers | OKTA Appreciates by 19.2%; Here Are 20 Stocks Moving Premarket (Aug 27)
U.S. stock futures rose, led by Nvidia (+4.7%) on strong Q2 revenue and guidance. Salesforce (+13%) and Okta (+19.2%) also gained, while HP fell 7.5%. Investors await BBY, WDAY, AFRM, GAP earnings and Jackson Hole symposium signals.
08-27 16:51
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Published in Critical Care Medicine, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HEND...
08-26 20:17
VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.57) by 49.12 percent. This is a 1316.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $398.657 thousand...
08-14 04:42
VolitionRx Issues Shares to Settle Convertible Note Obligations
VolitionRX ( ($VNRX) ) just unveiled an update. VolitionRx Limited disclosed th...
08-08 05:32
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- ...
07-30 20:17
VolitionRx Shareholders Approve Governance and Capital Changes
VolitionRX ( ($VNRX) ) has provided an update. On July 17, 2026, VolitionRx hel...
07-22 04:57
VolitionRx Partners With Sysmex To Streamline Volition's Nu.Q NETs H3.1 Assay
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO:6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.
06-17 20:16
VolitionRx Announces Pricing of $4.6 Million Public Offering
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx L...
06-08 06:30
